WithdrawnNo phase
Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
Reason given: Unable to support implementation.
Key facts
- Where
- Shanghai, ChinaSee the 2 sites
Where in China
- Shanghai East HospitalShanghai, ChinaNo longer taking part
- Shanghai Pulmonary HospitalShanghai, ChinaNo longer taking part
Trial details
- Who runs it
- Shanghai Pulmonary Hospital, Shanghai, China
- Trial code
- NCT06895941
- Record updated
- 8 April 2025
- Original description
The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.Read full original descriptionShow less
The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.
Inclusion: -.
Exclusion: -.